Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making. (PubMed, Reports (MDPI)) - Sep 25, 2026 - "The patient achieved a complete metabolic response without severe adverse events and has remained progression-free for 15 months. This case illustrates the feasibility and potential clinical activity of the chemotherapy-free Pola-R regimen for frail older patients with DLBCL, underscoring the critical role of integrating GA and SDM to individualize therapy and honor patient goals."
Journal • Alzheimer's Disease • B Cell Lymphoma • Cognitive Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Kento Ono; Ryusuke Horaguchi; Shohei Kikuchi; Tomoki Minemura; Tsutomu Sato
|